---
title: "Reducing ASCVD Risk, New FDA Approvals & More: Your August Monthly Beat"
---

Reducing ASCVD Risk, New FDA Approvals & More: Your August Monthly Beat…

| View in browser AUGUST   Industry Updates FDA FDA approves drug to reduce risk of serious kidney and heart complications in adults with chronic kidney disease associated with type 2 diabetes   Diabetes Care The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58   New England Journal of Medicine New study examines CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis   American Heart Association Microvascular disease and incident heart failure among individuals with type 2 diabetes mellitus   Journal of the American College of Cardiology ACC releases expert statement on managing hypertryglyceridemia to reduce ASCVD risk   American Heart Association American Heart Association/American Stroke Association release a scientific statement on the primary care of adult patients after stroke     Cardiometabolic Beat - New Episode Adam DeVore, MD, MHS  Listen in as Dr. Adam DeVore, Cardiologist and Associate Professor of Medicine at Duke University School of Medicine in Durham, North Carolina shares results from the CONNECT-HF trial.   New Senior Planning Committee Members & Specialized Roles New Planning Committee Member:       New Senior Planning Committee Roles Women’s Health & Cardiometabolic Risk Educational Planning Advisor: Ethnic & Racial Disparities in Cardiometabolic Health Educational Planning Advisor: READ FULL PRESS RELEASE   Best Blog Read More           Cardiometabolic Health Congress, 1801 North Military, Suite 200, Boca Raton, Florida 33431, United States, 877.571.4700 Unsubscribe Manage preferences |
| --- |